Click here to close now.

SYS-CON MEDIA Authors: Carmen Gonzalez, Liz McMillan, Kevin Jackson, Peter Silva, Greg Wind

News Feed Item

Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024

LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024

Report Details

Needle-free injecting technologies - discover activities, developments, and prospects of leading companies

What does the future hold for makers of needle-free injection (NFI) products? See what's possible. Visiongain's updated report shows you data to 2024 for that industry and market. There you find analysis, trends, opportunities, and forecasting of revenues.

Our study analyses 14 leading developers and producers of those medical devices. You can now explore the future of NFI to introduce drugs, finding its potential. Discover how you can benefit.

Forecasts and other data for staying ahead in knowledge of those medical injectors

There you examine the industry for needleless injection and needle-free syringes - insulin injectors and other systems. Find what's happening. Potential exists for novel and improved subcutaneous, intradermal, intramuscular, and intravenous drug delivery.

That industry advances. In our report you assess product ranges, historical data, R&D, market shares, sales predictions, and growth rates. There you get quantitative and qualitative analyses. You also find 42 tables, 17 charts and three research interviews.

NFI technology - discover how to help your work, also finding where money lies

Avoid missing out. See how developers overcome problems with parenteral drug application, esp. benefiting use of biological drugs (biologics). You also discover potential revenues.

So the following sections outline what you get in our investigation.

Companies based in North America - what're their outlooks?

First our study gives you financial data and discussions for prominent North American NFI developers and manufacturers:
• Antares Pharma
• Bioject Medical Technologies
• Zogenix
• Activa
• D'Antonio Consultants International.

You also find profiles of these organisations:
• National Medical Products
• Medical International Technologies
• Penjet Corporation
• PharmaJet
• Valeritas.

Discover what the present and future hold for those companies. Also find the money. See revenue predictions to 2024 for the overall world industry for needle-free injection devices.

Hear, too, about developments and prospects of competitors in other countries.

Europe - outlooks for leading developers and producers of medical injection technology

Next our report analyses European-based specialists in that drug delivery:
• Akra Dermojet
• Crossject Medical Technology
• Injex Pharma
• Glide Pharma.

Many commercial opportunities exist, with expanding revenues possible this decade. Discover the best potentials. You find how companies gain advantages and raise sales.

In that work you see what affects the future - what influences success.

Events and forces for developing, producing, marketing, and selling NFI technologies

Our study explains issues affecting that industry and market from 2013 onwards, including these:
• Applications - pain management, vaccine delivery, treating diabetes, paediatric medicine, and other therapies
• Regulations in the US and Europe
• Developments stimulating and restraining that market, inc. allied and competing products.

You also investigate these forces:
• Jet injector devices, transdermal patches, microneedles, pen injectors, and other therapeutic systems
• Solid formulations and other challenges, innovations, and progress in therapy
• Deals, collaborations, and other changes affecting that sector.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Examine what stimulates and restrains that industry and market.

You discover, then, what the present and future hold. You also read opinions from our survey of companies. Stay ahead for information.

Ways Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024 helps you

In particular, our report gives you the following knowledge:
• Profiles of 14 leading companies - assess products, strategies, and results
• Competition and opportunities - explore what affects the needle-free injectors industry, finding what influences its sales and determines its future
• Revenues to 2024 for that market at world level - discover prospects for success.

That work helps people interested in the future of pharmaceuticals and related instruments, containers, and accessories.

Analysis found nowhere else - discover the future of those devices and applications

Our work gives independent analysis. There you receive business intelligence found only in our report. You're free to choose, and our work lets you discover where the money lies.

With that investigation you're less likely to fall behind in information or miss opportunity. See there how you could benefit your research, analysis, and decisions. So avoid missing out.

Also find how you could save time and get recognition for insight, raising your influence.

1. Executive Summary

1.1 Leading NFI Device Manufacturers: Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
1.4 Aims, Scope and Format of the Report
1.5 Glossary of Terms

2. Introduction to Needle-Free Injection

2.1 What is Needle-Free Drug Delivery?
2.1.1 History of Needle-Free Injections: From Military to Clinic
2.1.2 Modern Needle-Free Devices: Concept of High Pressure Fluid Jet
2.2 What is the Rationale for Needle-Free Injections?
2.3 Applications of Needle-Free Drug Delivery
2.3.1 Pain Management: Using NFI Devices to Administer Lidocaine
2.3.2 Vaccine Delivery: Improving Immune Response
2.3.3 Insulin Delivery: Jet Injection Enhances Drug Distribution
2.3.4 Paediatrics: Alleviating Childhood Anxiety and Phobia
2.4 Regulation of Needle-Free Delivery Devices
2.4.1 The US Regulation System: Prolonged Approval Process
2.4.2 The European Regulation System: Manufacturers Seeking EU Approval First?
2.5 Advantages and Disadvantages of Needle-Free Systems

3. The Global Needle-Free Injection Device Market, 2013-2024

3.1 The Global Needle-Free Injection Device Market, 2012
3.2 The Global Needle-Free Injection Device Market: Revenue Forecast, 2013-2024
3.3 How Will the Market Shares of Leading Sectors Change From 2013-2024?
3.4 What Will Drive the Global Needle-Free Injection Device Market Between 2014 and 2024?
3.5 What Factors are Likely to Restrain the Global Needle-Free Injection Device Market Between 2014 and 2024?
3.6 The Global Jet Injector Device Market, 2012
3.6.1 The Global Jet Injector Device Market: Revenue Forecast, 2013-2024
3.6.2 The Global Jet Injector Device Market: Industry Trends, 2013-2024
3.7 The Global Competing Technologies Market, 2012
3.7.1 The Global Competing Technologies Market: Revenue Forecast, 2013-2024
3.7.2 The Global Competing Technologies Market: Industry Trends, 2013-2024
3.7.2.1 Transdermal Patches: Attractive and Cheap Option
3.7.2.2 Microneedle Technology: Huge Potential for Mass Vaccinations
3.7.2.3 Metered Dose Inhalers: Change in Device Propellant to Drive Adoption

4. The Leading North American Needle-Free Injection Device Manufacturers, 2013

4.1 Antares Pharma
4.1.1 Needle-Free Products
4.1.1.1 Vision™: Delivering Liquid Insulin or Human Growth Hormone
4.1.1.2 Vibex™: Hidden Needle to Alleviate Patient Fear
4.1.1.3 Pen Injector: Devices Being Used Clinical Testing
4.1.2 Sales Performance, 2012
4.1.3 Needle-Free Injection Device Pipeline
4.1.3.1 Vibex™ MTX: Targeting Growing Population of RA Sufferers
4.1.3.2 Vibex™ QS (QuickShot): Modified Vibex to Offer Improved Function
4.1.3.3 OTREXUP™: Combining Vibex MTX and Methotrexate
4.2 Bioject Medical Technologies
4.2.1 Needle-Free Products
4.2.1.1 Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
4.2.1.2 Vitajet™: Low-cost Insulin Delivery System
4.2.1.3 ZetaJet™: Auto-disable Feature Improves User Safety
4.2.2 Sales Performance
4.2.3 Needle-Free Injection Device Pipeline
4.2.3.1 Intradermal Pen Injector: Targeted Drug Delivery
4.2.3.2 Iject®: Providing Tailored Depth of Penetration
4.2.3.3 Jupiter Jet: Multi Dosing With Single Loaded Syringe
4.2.4 Collaborations
4.2.4.1 MPI Research: Seeking Drug/Device Combinations
4.2.4.2 World Health Organisation (WHO): the Push to Eradicate Infectious Disease in Developing Countries
4.3 Zogenix
4.3.1 Needle-Free Products
4.3.1.1 Sumavel® DosePro®: Rapid Acting Migraine Relief
4.3.2 Sales Performance, 2012
4.3.3 Needle-Free Injection Device Pipeline
4.3.3.1 Relday™: Needle-based Alterative for Improved Drug Distribution
4.3.4 Collaborations
4.3.5 Manufacturing
4.4 Activa Brand Products, Inc.
4.4.1 Technology: the Activa Family for Diabetics
4.4.2 Needle-Free Products
4.4.2.1 Product Advantages
4.5 D'Antonio Consultants International Inc. (DCI)
4.5.1 Needle-Free Products
4.5.1.1 LectraJet®: Lightweight Device Reduces User Fatigue
4.5.2 Needle-Free Injection Device Pipeline
4.5.2.1 Low Workload Jet Injector: Single-shot Manuel System
4.5.2.2 Multi Channel Jet Injector: For Simultaneous Vaccine Delivery
4.6 National Medical Products, Inc.
4.6.1 Needle-Free Products
4.6.1.1 J-Tip®: Offering Needle-free Administration of Anaesthesia
4.7 Medical International Technologies
4.7.1 Needle-Free Products
4.7.1.1 MED-JET®: Extremely Thin Orifice Offers Improved Drug Absorption
4.7.2 Sales Performance, 2012
4.7.3 Increased Awareness Through Globalisation
4.8 Penjet Corporation
4.8.1 Needle-Free Products
4.8.1.1 Penjet®: Nitrogen-powered Device Allows Efficient Storage
4.8.2 Applications
4.8.2.1 Multi-Component Drugs
4.8.2.2 Lyophilised Drug Delivery
4.8.2.3 Small Pox Vaccination
4.9 PharmaJet
4.9.1 Needle-Free Products
4.9.1.1 STRATIS®: Drug Delivery in Less Than a Second
4.9.2 Applications
4.9.3 Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
4.10 Valeritas
4.10.1 Needle-Free Products
4.10.1.1 Mini-Ject™: Potential Delivery of Lyophilised Drugs May Open Huge Opportunities for Valeritas

5. The Leading European Needle-Free Injection Device Manufacturers, 2013

5.1 Akra Dermojet
5.1.1 Needle-Free Products
5.1.1.1 Dermojet® "HR": User-Friendly Design Allows Use in High Intensive Applications
5.1.1.2 DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
5.1.1.3 Automatic DERMOJET®
5.2 Crossject Medical Technology
5.2.1 Technology: Highly Customisable Device Allows Tailoring to Specific Drugs
5.2.2 Needle-Free Products
5.2.2.1 Zeneo®: Gas Propellant Generated Upon Injection
5.3 Injex Pharma AG
5.3.1 Needle-Free Products
5.3.1.1 INJEX30®: First Multiple Application Needle-Free Device?
5.4 Glide Pharma
5.4.1 Needle-Free Products
5.4.1.1 Glide SDI®
5.4.1.2 Applications
5.4.2 Advantages
5.4.2.1 Injecting Solid Formulations
5.4.2.2 Pharmaceutical Companies
5.4.3 Collaboration with Pfenex Inc. To Aid Delivery of Solid Dose Vaccine

6. Qualitative Analysis of the Global Needle-Free Injection Device Market, 2013-2024

6.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2013-2024
6.1.1 Strengths
6.1.1.1 A Less Painful Alternative to Needle-Based Injections
6.1.1.2 No Specialist Training Required for Delivery
6.1.1.3 Reduced Transport Costs
6.1.2 Weaknesses
6.1.2.1 Expensive Technology
6.1.2.2 Inefficient Manufacturing Process
6.1.2.3 Off Patent/Generics Require Reformulating Prior to Use in Needle-Free Delivery Systems
6.1.3 Opportunities
6.1.3.1 Emerging Economies
6.1.3.2 Mass Immunisation Programmes
6.1.3.3 Potential Delivery of Vaccines
6.1.3.4 Patent Expiry of Leading Drugs will Increase Competition
6.1.4 Threats
6.1.4.1 Traditional Needles and Syringes are Cheap to Mass Produce
6.1.4.2 Limited Clinical Data
6.1.4.3 Increased Scrutiny from Regulatory Bodies
6.1.4.4 Medical Device Excise Tax
6.2 STEP Analysis of the Global Needle-Free Injection Device Market, 2013-2024
6.2.1 Social Factors
6.2.2 Technological Developments
6.2.3 Economical Pressures
6.2.4 Political Issues

7. Opinions from Our Industry Survey

7.1 Interview with Zogenix Technologies
7.1.1 Recent Technological Developments in Needle-Free Systems
7.1.2 Competing Technologies and Market Opportunities
7.1.3 Market Restraints and Future Directions
7.2 Interview with Bioject Medical Technologies
7.2.1 Finding a Competitive Edge over Market Rivals
7.2.2 Market Dynamics and Company Collaborations
7.2.3 Potential of Emerging Markets and Regulatory Concerns
7.3 Interview with Team Consulting
7.3.1 Historical Development of the Needle-Free Market
7.3.2 Company Activities and Overcoming the Skin Barrier
7.3.3 Challenges and Limits to Market Growth
7.3.4 Prospects for the Needle-Free Market

8. Conclusions

8.1 The Global Needle-Free Injection Device Market, 2013-2024
8.2 Zogenix Dominated the Global Needle-Free Injection Device Market in 2012
8.3 Strong Company Pipeline Will Help Drive the Market
8.4 Concluding Remarks

List of Tables

Table 1.1 Currency Exchange Rates
Table 2.1 Examples of Needle-Free Vaccine Delivery Systems, 2013
Table 2.2 Examples of Needle-Free Insulin Delivery Systems, 2013
Table 2.3 Advantages and Disadvantages of Needle-Free Injection, 2013
Table 3.1 The Global Needle Free Injection Device Market: Revenue ($m) and Market Share (%) by Technology, 2012
Table 3.2 The Global Needle-Free Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %) by Technology, 2013-2024
Table 3.3 The Global Needle-Free Injection Device Market: Market Share (%) by Technology, 2013-2024
Table 3.4 The Global Needle-Free Injection Device Market: Drivers and Restraints, 2013-2024
Table 3.5 Patent Expiries for Leading Drugs, 2014-2016
Table 3.6 Classification of Jet Injector Devices, 2013
Table 3.7 The Global Jet Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.8 The Global Competing Needle-Free Technologies Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.9 Insulin Inhalation Systems in Development, 2013
Table 3.10 Vaccine Inhalers in Development, 2013
Table 4.1 Antares Pharma: Key Facts, 2013
Table 4.2 Antares Pharma Licensing Partnerships, 2013
Table 4.3 Antares Pharma: Revenue ($m) & Revenue Share (%) by Business Segment, 2012
Table 4.4 Antares Pharma: Product Revenue ($m, CAGR %) by Category, 2010-2012
Table 4.5 Bioject Medical Technologies: Key Facts, 2013
Table 4.6 Bioject: Revenue ($m) and Revenue Share (%), by Product Line, 2010
Table 4.7 Bioject: Summary of Technologies
Table 4.8 Zogenix: Key Facts, 2013
Table 4.9 Zogenix: Summary of Technology
Table 4.10 Zogenix: Revenue ($m) and Revenue Share (%) by Business Segment, 2012
Table 4.11 Activa Brand Products: Key Facts, 2013
Table 4.12 D'Antonio Consultants: Key Facts, 2013
Table 4.13 National Medical Products: Key Facts, 2013
Table 4.14 Medical International Technologies: Key Facts, 2013
Table 4.15 Medical International Technologies: Revenue ($m, CAGR %), 2009-2012
Table 4.16 PenJet Corporation: Key Facts, 2013
Table 4.17 PharmaJet: Key Facts, 2013
Table 4.18 Valeritas: Key Facts, 2013
Table 5.1 Akra Dermojet: Key Facts, 2013
Table 5.2 Akra Dermojet: Summary of Technology
Table 5.3 Crossject Medical Technology: Key Facts, 2013
Table 5.4 Injex Pharma AG: Key Facts, 2013
Table 5.5 Glide Pharma: Key Facts, 2013
Table 6.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2013-2024
Table 6.2 Average Price for Needle-Free Drug/Vaccine Delivery Technology, 2013
Table 6.3 Patent Expiries for Leading Drugs, 2014-2016
Table 6.4 The Global Needle-Free Injection Market: STEP Analysis, 2013-2024
Table 8.1 The Global Needle-Free Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %) and Market Share (%) by Technology, 2012, 2015, 2018, 2021 and 2024

List of Figures

Figure 3.1 The Global Needle Free Injection Device Market: Share (%) by Technology, 2012
Figure 3.2 The Global Needle Free Injection Device Market: Revenue ($m) by Technology, 2012
Figure 3.3 The Global Needle-Free Injection Device Market: Revenue Forecast ($m), 2013-2024
Figure 3.4 The Global Needle-Free Injection Device Market: Share (%) by Technology, 2018
Figure 3.5 The Global Needle-Free Injection Device Market: Share (%) by Technology, 2024
Figure 3.6 The Global Jet Injection Device Market: Revenue Forecast ($m), 2013-2024
Figure 3.7 The Global Competing Needle-Free Technologies Market: Revenue Forecast ($m), 2013-2024
Figure 4.1 Antares Pharma: Revenue Share (%) by Business Segment, 2012
Figure 4.2 Antares Pharma: Product Revenue ($m) by Category, 2010-2012
Figure 4.3 Bioject: Revenue Share (%) by Product Line, 2010
Figure 4.4 Bioject: Revenue ($m), 2010-2012
Figure 4.5 Zogenix: Revenue Share (%) by Business Segment, 2012
Figure 4.6 Zogenix: Revenue ($m) by Business Segment, 2010-2012
Figure 4.7 Medical International Technologies: Revenue ($m), 2009-2012
Figure 6.1 The Transport Process for a Vaccine
Figure 8.1 The Global Needle-Free Injection Device Market: Revenue Forecast ($m) by Technology, 2012, 2015, 2018, 2021 and 2024
Figure 8.2 The Global Needle-Free Injection Device Market: Leading Companies by Revenue ($m), 2012

Companies Listed

3M
Actavis
Activa Brand Products
Aerogen
Akra Dermojet
ALZA Pharmaceuticals
Ankara University
Antares Pharma
Aradigm Corporation
Astellas Pharma
AstraZeneca
Battelle
Bill and Melinda Gates Foundation
Bioject Medical Technologies
BioValve Technologies
Bristol-Myers Squibb
Cambridge Consultants
CDC Measles Eradication Committee
Centre for Devices and Radiological Health (CDRH)
Centre for Disease Control and Prevention (CDC)
China State Food and Drug Administration (SFDA)
Covidien
Crossject Medical Technology
CSL Behring
CSL Limited
Daewoong Pharmaceuticals
Dance Pharmaceuticals
D'Antonio Consultants International
Diabetes Management International
Dr. Reddy's Laboratories
Durect Corporation
Echo Therapeutics
Eli Lilly
Eurojet Medical
European Union
Ferndale Pharma Group
Ferring Pharmaceuticals
Food and Drug Administration (FDA)
Georgia Tech University
GlaxoSmithKline (GSK)
Glide Pharma
Harvard University
Injex Pharma AG
JCR Pharmaceuticals
Jiangsu Hualan Medical International Technologies
Johnson & Johnson
Mallinckrodt Pharmaceuticals
MannKind
Meda Pharmaceuticals
Medical International Technologies
MedImmune
Merck & Co.
Merck Serono
Mglas AG
Minnesota Rubber and Plastics (MRP)
MPI Research
Mylan
National Medical Products
Nektar Therapeutics
North Carolina University
Novartis
Novo Nordisk
Nypro Limited
Patheon
Penjet Corporation
Pfenex Inc.
Pfizer
PharmaJet
Philips Medical
Sanofi-Aventis
Sanofi-Pasteur
Takeda
Team Consulting
Teva Pharmaceuticals
UCB
University of Colorado
US Army Medical Research Institute of Infectious Disease (USAMRIID)
Valeritas
Vaxxas
Weston Medical
World Health Organization (WHO)
Zogenix
Zomajet
Zosano Pharma

Read the full report:
Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024
http://www.reportbuyer.com/pharma_healthcare/medical_devices/medical_device_leader_series_top_needle_free_injection_device_manufacturers.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
DevOps tasked with driving success in the cloud need a solution to efficiently leverage multiple clouds while avoiding cloud lock-in. Flexiant today announces the commercial availability of Flexiant Concerto. With Flexiant Concerto, DevOps have cloud freedom to automate the build, deployment and operations of applications consistently across multiple clouds. Concerto is available through four disruptive pricing models aimed to deliver multi-cloud at a price point everyone can afford.
Today, IT is not just a cost center. IT is an enabler and driver of business. With the emergence of the hybrid cloud paradigm, IT now has increasingly more capabilities to create new strategic opportunities for a business. Hybrid cloud allows an organization to utilize multi-tenant public clouds, dedicated private clouds, bare metal hosting, and the associated support and services for the right use cases through an on-demand, XaaS model. This model of IT creates tremendous opportunities for busi...
Docker is an excellent platform for organizations interested in running microservices. It offers portability and consistency between development and production environments, quick provisioning times, and a simple way to isolate services. In his session at DevOps Summit at 16th Cloud Expo, Shannon Williams, co-founder of Rancher Labs, will walk through these and other benefits of using Docker to run microservices, and provide an overview of RancherOS, a minimalist distribution of Linux designed...
Business as usual for IT is evolving into a “Make or Buy” decision on a service-by-service conversation with input from the LOBs. How does your organization move forward with cloud? In his general session at 16th Cloud Expo, Paul Maravei, Regional Sales Manager, Hybrid Cloud and Managed Services at Cisco, discusses how Cisco and its partners offer a market-leading portfolio and ecosystem of cloud infrastructure and application services that allow you to uniquely and securely combine cloud busi...
Businesses are looking to empower employees and departments to do more, go faster, and streamline their processes. For all workers – but mobile workers especially – utilizing the cloud to reconnect documents and improve processes without destructing existing workflows can have a dramatic impact on productivity. In his session at 16th Cloud Expo, Mark Grilli, vice president of Acrobat Solutions marketing at Adobe Systems Incorporated, will outline new ways that the cloud is changing the way peo...
Wearable technology was dominant at this year’s International Consumer Electronics Show (CES) , and MWC was no exception to this trend. New versions of favorites, such as the Samsung Gear (three new products were released: the Gear 2, the Gear 2 Neo and the Gear Fit), shared the limelight with new wearables like Pebble Time Steel (the new premium version of the company’s previously released smartwatch) and the LG Watch Urbane. The most dramatic difference at MWC was an emphasis on presenting we...
SYS-CON Events announced today that Vitria Technology, Inc. will exhibit at SYS-CON’s @ThingsExpo, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Vitria will showcase the company’s new IoT Analytics Platform through live demonstrations at booth #330. Vitria’s IoT Analytics Platform, fully integrated and powered by an operational intelligence engine, enables customers to rapidly build and operationalize advanced analytics to deliver timely business outcomes ...
Are your applications getting in the way of your business strategy? It’s time to rethink your IT approach. In his session at 16th Cloud Expo, Madhukar Kumar, Vice President, Product Management at Liaison Technologies, will discuss a new data-centric approach to IT that allows your data, not applications, to inform business strategy. By moving away from an application-centric IT model where data integration and analysis are subservient to the constraints of applications, your organization will b...
SYS-CON Events announced today that Liaison Technologies, a leading provider of data management and integration cloud services and solutions, has been named "Silver Sponsor" of SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York, NY. Liaison Technologies is a recognized market leader in providing cloud-enabled data integration and data management solutions to break down complex information barriers, enabling enterprises to make sm...
SYS-CON Events announced today that MangoApps will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY., and the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MangoApps provides private all-in-one social intranets allowing workers to securely collaborate from anywhere in the world and from any device. Social, mobile, and eas...
WSM International has launched a DevOps services division that offers assessment, consulting and implementation to large enterprises and organizations with complex infrastructures. The concept of DevOps is to blend information technology (IT) software development with operations to optimize the computing infrastructure according to the specific needs of the organization. According to a recent press release from Gartner, "By 2016, DevOps will evolve from a niche strategy employed by large cloud ...
SYS-CON Events announced today that Solgenia will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY, and the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Solgenia is the global market leader in Cloud Collaboration and Cloud Infrastructure software solutions. Designed to “Bridge the Gap” between Personal and Professional S...
SYS-CON Events announced today that QTS Realty Trust, one of the nation’s largest and fastest-growing providers of data center facilities and cloud services and a leader in security and compliance, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. QTS Realty Trust, Inc. (NYSE: QTS) is a leading national provider of data center solutions and fully managed services, and a leader in security and compliance...
SYS-CON Events announced today that WSM International (WSM), the world’s leading cloud and server migration services provider, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. WSM is a solutions integrator with a core focus on cloud and server migration, transformation and DevOps services.
Sematext is a globally distributed organization that builds innovative Cloud and On Premises solutions for performance monitoring, alerting and anomaly detection (SPM), log management and analytics (Logsene), and search analytics (SSA). We also provide Search and Big Data consulting services and offer 24/7 production support for Solr and Elasticsearch.